lunes, 7 de diciembre de 2015

Management of Thyroid Nodular Disease: Current Cytopathology Classifications and Genetic Testing. - PubMed - NCBI

Management of Thyroid Nodular Disease: Current Cytopathology Classifications and Genetic Testing. - PubMed - NCBI



 2016 Jan;25(1):1-16. doi: 10.1016/j.soc.2015.08.001. Epub 2015 Oct 31.

Management of Thyroid Nodular Disease: Current Cytopathology Classifications and Genetic Testing.

Abstract

Preoperative diagnosis and operative planning for patients with thyroid nodules has improved over the last decade. The Bethesda criteria for cytopathologic classification of thyroid nodule aspirate has enhanced communication between pathologists and clinicians. Multiple genetic tests, including molecular markers and the Afirma gene expression classifier, have been developed and validated. The tests, along with clinical and radiologic information, are most useful in the setting of indeterminate cytology. The development of an updated diagnostic and treatment algorithm incorporating all available tests will help standardize the management of patients with nodular thyroid disease and reduce variation and inefficiencies in care.
Copyright © 2016 Elsevier Inc. All rights reserved.

KEYWORDS:

Afirma; Bethesda classification; Genetic testing; Molecular markers; Thyroid nodules

PMID:
 
26610771
 
[PubMed - in process]

No hay comentarios:

Publicar un comentario